Global & Specialty Society Guidelines Beyond AASLD 2023 and ADA 2026
How 12 hepatology, diabetes, endocrinology, cardiology, pediatric, radiology, portal hypertension, and international societies screen and stage MASLD/MASH.
Because MASLD sits at the crossroads of metabolism, heart health, hormone balance, kidney function, and liver scarring, liver societies aren't the only ones writing the rulebook anymore. Over the past three years, European liver-diabetes-obesity societies (EASL-EASD-EASO), heart specialists (AHA), endocrinologists (AACE), gastroenterologists (AGA), pediatricians (NASPGHAN/AAP), radiologists (ACR/SRU), and Asian-Pacific/Latin American panels have all published dedicated guidance.
While nearly every adult society agrees on starting with FIB-4 and following up with elastography or ELF, specialty guidelines add life-saving protections you won't see on a single flowchart: AHA confirms statins are safe and vital for your heart, AGA flags 'lean' MASLD at normal BMI, APASL lowers BMI screening cutoffs to 23 kg/m2 in Asian adults, and NASPGHAN warns never to use adult FIB-4 in children.
EASL–EASD–EASO 2024 Joint European Case-Finding Cascade1
- Type 2 diabetes (regardless of liver enzyme levels)
- Abdominal obesity + ≥1 additional cardiometabolic risk factor
- Persistently abnormal liver enzymes or steatosis on imaging
Quantify weekly alcohol (MASLD vs. MetALD vs. ALD) and exclude secondary liver diseases.
- VCTE (FibroScan): <8.0 kPa rules out advanced fibrosis; ≥8.0 kPa prompts intensive care or specialist evaluation
- ELF™ (<9.8) or FibroTest when elastography is unavailable
Manage cardiometabolic health, weight, and diabetes in primary/endocrine care; reassess FIB-4 every 1–3 years.
Confirm staging (MRE, second NIT, or biopsy if discordant), evaluate MASH pharmacotherapy (F2–F3), or initiate cACLD/portal hypertension care (≥10–15 kPa).
12 Professional Society Guidelines Compared Across Specialties
| Society & Specialty | Guideline / Statement | Target Screening Population | Distinctive Diagnostic Contribution |
|---|---|---|---|
| AASLD NILDA Trilogy US Hepatology (GRADE) |
Blood, Imaging & Portal HTN NILDA Guidelines (2025)2–4 | Adults with steatosis, T2D, obesity/MetS, persistent ↑ALT/AST, or family history of MASLD cirrhosis | Formal GRADE evidence ratings across blood and imaging NITs; introduces Spleen Stiffness Measurement (SSM ≤21 vs. ≥50 kPa) alongside VCTE and platelets for portal hypertension.4 |
| EASL–EASD–EASO European Liver, Diabetes & Obesity |
Joint Clinical Practice Guidelines on MASLD (2024)1 | T2D, abdominal obesity + ≥1 metabolic factor, or abnormal liver enzymes (not general population) | Formalizes the Steatotic Liver Disease (SLD) umbrella (including MetALD), age-adjusted FIB-4 (<2.0 at age ≥65), and flexible VCTE/ELF primary-to-specialty pathways. |
| AACE / AASLD US Endocrinology |
Primary Care & Endocrinology Guideline (2022; update in progress)5 | T2D, prediabetes, obesity, steatosis, PCOS, hypothyroidism, hypogonadism, GH deficiency | Highlights endocrine conditions that accelerate MASH and embeds fibrosis screening directly into routine diabetes and obesity clinic visits. |
| AGA US Gastroenterology |
Clinical Care Pathway (2021/2023) & Lean MASLD CPU (2022)6,7 | ≥2 metabolic risk factors, T2D, AND non-obese/“lean” adults (BMI <25 kg/m², or <23 Asian) with visceral/metabolic risk | 7%–20% of MASLD occurs at normal BMI. Advises FIB-4 + elastography plus targeted rule-out of celiac disease, AAT deficiency, lipodystrophy, and genetic variants in lean patients.7 |
| AHA / ACC US Cardiology |
AHA Scientific Statement: NAFLD & Cardiovascular Risk (2022)8 | Bidirectional: screen MASLD patients for ASCVD risk, and evaluate metabolic heart patients for liver fibrosis | Heart disease is the #1 cause of death in MASLD. Frames MASLD as an ASCVD risk enhancer and confirms statins are safe and protective in MASLD and compensated cirrhosis (mild ALT <3× ULN is not a reason to stop statins).8 |
| NASPGHAN & AAP US Pediatrics |
Pediatric NAFLD/MASLD Clinical Practice Guideline & Updates9 | Children ages 9–11 with obesity (BMI ≥95th percentile) or overweight (85th–94th) + cardiometabolic risk factors | Never use adult FIB-4 in children/teens (age numerator creates false-normal scores). Screen with sex-specific pediatric ALT (ULN = 25 U/L boys, 22 U/L girls; persistent ≥50 boys / ≥44 girls [≥2× ULN] or ≥80 U/L prompts specialist workup).9 |
| ACR & SRU Radiology & Ultrasound |
SRU Consensus (“Rule of 4s”) (2020/2024) & ACR Criteria10 | Patients referred for acoustic shear-wave elastography (pSWE / 2D-SWE) or cross-sectional imaging | Establishes vendor-neutral acoustic SWE cutoffs (≤5 normal, <9 rule-out cACLD, 9–13 gray zone, >13 probable cACLD, >17 kPa probable CSPH) across hospital ultrasound scanners. |
| Baveno VII Portal Hypertension |
Baveno VII Consensus (2022) & ANTICIPATE-NASH11 | Compensated advanced chronic liver disease (cACLD, VCTE ≥10 kPa) | Defines the Rule of 5s (10–15–20–25 kPa) and ANTICIPATE-NASH (combining BMI + LSM + platelets because VCTE ≥25 kPa alone overestimates CSPH when BMI ≥30 kg/m²). |
| APASL Asian-Pacific Hepatology |
APASL Clinical Practice Guidelines (2020 / 2025)12 | Hepatic steatosis + Asian overweight threshold (BMI ≥23 kg/m² or waist ≥90 cm men / ≥80 cm women) or T2D | Recognizes earlier visceral adiposity in Asian populations and provides explicit pathways for dual-etiology liver disease (eg, MASLD coexisting with chronic HBV). |
| NICE (NG49), ALEH & WGO UK, Latin America & Global |
NICE NG49 / MIBs; ALEH Guidance; WGO Global Cascade13,14 | Primary care MASLD cohorts, Hispanic/Indigenous high-risk populations, and resource-limited clinics | NICE pioneered primary-care ELF testing; ALEH highlights high PNPLA3 burden across Latin America; WGO supplies resource-tiered cascades where FibroScan/MRE are unavailable. |
| OMA & KDIGO / CRHM Obesity & Nephrology |
OMA MASLD Statement & Cardio-Renal-Hepatic-Metabolic Consensus15 | Patients in medical weight-management programs or living with chronic kidney disease (CKD) | MASLD doubles CKD risk: pairs liver fibrosis staging (FIB-4 / VCTE) with routine eGFR + spot urine albumin-to-creatinine ratio (UACR) co-screening. |
Where Experts Still Debate: 4 Unresolved Questions Patients Encounter
1. USPSTF Silence vs. Specialty Consensus
While AASLD, ADA 2026, EASL, AGA, and AACE all endorse targeted FIB-4 screening in T2D and metabolic obesity, the US Preventive Services Task Force (USPSTF) has not issued an adult MASLD screening grade. Documenting underlying ICD-10 metabolic and hepatic codes (eg, T2D, elevated transaminases, or imaging steatosis) helps prevent commercial payer denials for second-line ELF or VCTE.
2. FIB-4 Sensitivity Gap for F2 MASH in Diabetes
FIB-4 <1.3 reliably rules out cirrhosis, yet prospective diabetes studies show it can miss 35%–45% of T2D patients who already have moderate (F2) “at-risk” MASH. Several academic centers therefore pair FIB-4 with the SAFE score or perform direct point-of-care FibroScan in diabetes clinics.
3. Age ≥65 FIB-4 (<2.0) Trade-Off
Raising the low-risk FIB-4 cutoff from <1.3 to <2.0 at age 65+ cuts false-positive referrals in half, but lowers sensitivity in older adults with long-standing diabetes. Clinicians should still consider VCTE or ELF at FIB-4 1.3–1.99 when clinical suspicion is high.
4. Why kPa Cutoffs Differ Across Reports (8 vs. 9 vs. 10 kPa)
FibroScan VCTE uses 8.0 kPa to screen for ≥F2 fibrosis, hospital ultrasound ARFI-SWE uses 9.0 kPa (SRU Rule of 4s), Baveno VII uses 10.0 kPa to suspect cACLD (F3–F4), and MASH drug guidance uses 10–15 kPa for high-confidence F2–F3 treatment selection.